,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3FUAQ'}, 'Id': 'a0P2P000002zt3FUAQ', 'Event_Date__c': '2013-05-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqO9QAK'}, 'change': None}]",May 2013,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Subcommittee recommend changes to the Special Authority, with the aim to align it to the new GOLD classification and the COPD Assessment Test (CAT).', 'fs': 'The Subcommittee recommend changes to the Special Authority, with the aim to align it to the new GOLD classification and the COPD Assessment Test (CAT).', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf "" target=""_blank"">Respiratory Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf "" target=""_blank"">Respiratory Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 24 May 2013.', 'fs': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 24 May 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3HUAQ'}, 'Id': 'a0P2P000002zt3HUAQ', 'Event_Date__c': '2013-05-24', 'Event_Description__c': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 24 May 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf "" target=""_blank"">Respiratory Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommend changes to the Special Authority, with the aim to align it to the new GOLD classification and the COPD Assessment Test (CAT).', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqPZQA0'}, 'change': None}, {'Summary': {'s': 'PTAC asked to review the data before making a recommendation.', 'fs': 'PTAC asked to review the data before making a recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2013', 'fs': 'Aug 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3IUAQ'}, 'Id': 'a0P2P000002zt3IUAQ', 'Event_Date__c': '2013-08-30', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'PTAC asked to review the data before making a recommendation.', 'Formatted_Date__c': 'Aug 2013', 'Status_History__c': 'a132P000000AqS9QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2014', 'fs': 'Apr 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.', 'fs': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3JUAQ'}, 'Id': 'a0P2P000002zt3JUAQ', 'Event_Date__c': '2014-04-30', 'Event_Description__c': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'Outcome__c': 'Recommended alteration to access criteria', 'Formatted_Date__c': 'Apr 2014', 'Status_History__c': 'a132P000000AqeAQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2014', 'fs': 'Aug 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 August 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 August 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3KUAQ'}, 'Id': 'a0P2P000002zt3KUAQ', 'Event_Date__c': '2014-08-14', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 August 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Aug 2014', 'Status_History__c': 'a132P000000AqkkQAC'}, 'change': None}, {'Summary': {'s': 'Recommended removing the requirement to record FEV1 reading on renewals.', 'fs': 'Recommended removing the requirement to record FEV1 reading on renewals.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2015-03.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2015-03.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 4 March 2015.', 'fs': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 4 March 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3LUAQ'}, 'Id': 'a0P2P000002zt3LUAQ', 'Event_Date__c': '2015-03-04', 'Event_Description__c': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 4 March 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2015-03.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'Outcome__c': 'Recommended alteration to access criteria', 'Summary__c': 'Recommended removing the requirement to record FEV1 reading on renewals.', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqsjQAC'}, 'change': None}, {'Summary': {'s': 'PTAC reiterated that diagnosis of COPD must include spirometry, but noted that FEV1 may not be useful to guide use of inhaled agents for COPD and considered that open listing the long-acting muscarinic-agents may be appropriate if the cost of these agents was lower.', 'fs': 'PTAC reiterated that diagnosis of COPD must include spirometry, but noted that FEV1 may not be useful to guide use of inhaled agents for COPD and considered that open listing the long-acting muscarinic-agents may be appropriate if the cost of these agents was lower.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2015', 'fs': 'Aug 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3MUAQ'}, 'Id': 'a0P2P000002zt3MUAQ', 'Event_Date__c': '2015-08-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Recommended alteration to access criteria', 'Summary__c': 'PTAC reiterated that diagnosis of COPD must include spirometry, but noted that FEV1 may not be useful to guide use of inhaled agents for COPD and considered that open listing the long-acting muscarinic-agents may be appropriate if the cost of these agents was lower.', 'Formatted_Date__c': 'Aug 2015', 'Status_History__c': 'a132P000000AqyMQAS'}, 'change': None}]",May 2013,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3GUAQ'}, 'Id': 'a0P2P000002zt3GUAQ', 'Event_Date__c': '2013-05-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqOOQA0'}, 'change': None}]",May 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2015', 'fs': 'Dec 2015', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3NUAQ'}, 'Id': 'a0P2P000002zt3NUAQ', 'Event_Date__c': '2015-12-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Dec 2015', 'Status_History__c': 'a132P000000Ar3XQAS'}, 'change': None}]",Dec 2015,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': 'This consultation proposes to remove the requirement to state FEV1 measurements when requesting renewals on tiotropium bromide.', 'fs': 'This consultation proposes to remove the requirement to state FEV1 measurements when requesting renewals on tiotropium bromide.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/consultation-2015-12-18-respiratory-products/"" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/consultation-2015-12-18-respiratory-products/"" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Jan 2016', 'fs': 'Jan 2016', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3OUAQ'}, 'Id': 'a0P2P000002zt3OUAQ', 'Event_Date__c': '2016-01-08', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/consultation-2015-12-18-respiratory-products/"" target=""_blank"">Consultation letter</a>', 'Summary__c': 'This consultation proposes to remove the requirement to state FEV1 measurements when requesting renewals on tiotropium bromide.', 'Formatted_Date__c': 'Jan 2016', 'Status_History__c': 'a132P000000Ar3mQAC'}, 'change': None}]",Jan 2016,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'From 1 March 2016, applicants will no longer need to state recent measurement of FEV1 data for renewal of LAMAs.', 'fs': 'From 1 March 2016, applicants will no longer need to state recent measurement of FEV1 data for renewal of LAMAs.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/notification-2016-02-03-respiratory-products/"" target=""_blank"">Notification letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/notification-2016-02-03-respiratory-products/"" target=""_blank"">Notification letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'The funding application has been Approved.', 'fs': 'The funding application has been Approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zt3PUAQ'}, 'Id': 'a0P2P000002zt3PUAQ', 'Event_Date__c': '2016-02-02', 'Event_Description__c': 'The funding application has been Approved.', 'Stage__c': 'Decision', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/notification-2016-02-03-respiratory-products/"" target=""_blank"">Notification letter</a>', 'Summary__c': 'From 1 March 2016, applicants will no longer need to state recent measurement of FEV1 data for renewal of LAMAs.', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar44QAC'}, 'change': None}]",Feb 2016,False,True
